The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US ...

Precision medicine, also known as personalised medicine, is transforming healthcare by providing tailored treatments to patients suffering from life-threatening conditions. We are all unique, and ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

AstraZeneca's EGFR inhibitor Tagrisso has become the first drug in the class to be approved in the EU as a treatment for a specific form of locally advanced, unresectable non-small cell lung ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

In 2023, the life sciences industry was rocked by generative artificial intelligence (GenAI), which showed the potential to revolutionise everything from genetic understanding and drug research to ...

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and Wales. Final draft ...

Bristol Myers Squibb's Opdivo has been approved in a subcutaneous injection formulation by the FDA, making treatment easier for patients and potentially adding years to the product's patent life.